Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPETE: Neoadjuvant AI + OFS vs Chemotherapy in Premenopausal HR+ Breast Cancer
NCT02532400Phase 3Terminated
- Sponsor
- Ruijin Hospital
- Start
- Mar 2016
- Primary completion
- Mar 2019
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of exemestane, anastrozole and goserelin in breast cancer (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Overall Response Rate at 7 months. Started Mar 2016; status: terminated.
02
Drugs
exemestaneanastrozolegoserelin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02532400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02532400.